M&G PLC Bei Gene, Ltd. Transaction History
M&G PLC
- $17.1 Billion
- Q3 2025
A detailed history of M&G PLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, M&G PLC holds 120,721 shares of BGNE stock, worth $27.4 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
120,721
Previous 170,202
29.07%
Holding current value
$27.4 Million
Previous $38.6 Million
29.07%
% of portfolio
0.16%
Previous 0.23%
Shares
7 transactions
Others Institutions Holding BGNE
# of Institutions
297Shares Held
30.4MCall Options Held
147KPut Options Held
195K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion16.25% of portfolio
-
Primecap Management CO Pasadena, CA5.08MShares$1.15 Billion0.91% of portfolio
-
Capital International Investors Los Angeles, CA5.05MShares$1.14 Billion0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.63MShares$370 Million0.06% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million7.05% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...